Canadian biotechnology company AbCellera Biologics has entered a new therapeutic antibody discovery collaboration with Israeli-based Teva Pharmaceutical Industries to discover new antibodies against membrane protein targets.

The current agreement follows a successful first collaboration completed between the two companies last year.

AbCellera founding chief executive officer Carl Hansen said: “We are excited to expand our relationship with the innovative team at Teva.

“This follow-on project marks an important step in establishing AbCellera's platform as an enabling technology for difficult target classes that have proven intractable by conventional antibody discovery methods.”

The deal will see AbCellera Biologics use its monoclonal antibody (mAb) screening platform to support the discovery of antibodies that modulate the function of an undisclosed membrane protein target elected by Teva Pharmaceutical.

"This agreement will be complementary to our existing antibody discovery process, with the potential to strengthen Teva’s capabilities in novel biologics discovery."

Teva Pharmaceutical Industries senior vice-president and global head Steffen Nock said: “We are pleased to extend our work with AbCellera utilising this company’s novel biologics technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This agreement will be complementary to our existing antibody discovery process, with the potential to strengthen Teva’s capabilities in novel biologics discovery.”

As part of the agreement, AbCellera will receive an upfront payment and research support, in addition to milestone and royalty payments based on Teva Pharmaceutical’s development and commercialisation of antibodies generated under the current partnership.

Further terms of the agreement have not yet been disclosed.

In January this year, AbCellera also collaborated with US-based company Pfizer to discover function-modulating antibodies against undisclosed membrane protein targets using its mAb screening platform.